BRPI0313664B8 - compostos inibidores de nucleosídeo fosforilase e nucleosidases, suas composições e seus usos - Google Patents

compostos inibidores de nucleosídeo fosforilase e nucleosidases, suas composições e seus usos

Info

Publication number
BRPI0313664B8
BRPI0313664B8 BRPI0313664A BR0313664A BRPI0313664B8 BR PI0313664 B8 BRPI0313664 B8 BR PI0313664B8 BR PI0313664 A BRPI0313664 A BR PI0313664A BR 0313664 A BR0313664 A BR 0313664A BR PI0313664 B8 BRPI0313664 B8 BR PI0313664B8
Authority
BR
Brazil
Prior art keywords
compounds
nucleosidases
compositions
inhibitor compounds
nucleoside phosphorylase
Prior art date
Application number
BRPI0313664A
Other languages
English (en)
Other versions
BR0313664A (pt
BRPI0313664B1 (pt
Inventor
Henning Lenz Dirk
Brian Evans Gary
Vladmirovna Zubkova Olga
Charles Tyler Peter
Hubert Furneaux Richard
L Schramm Vern
Original Assignee
Albert Einstein College Medicine Yeshiva Univ
Albert Einstein College Medicine Inc
Callaghan Innovation Res Limited
Com Affiliation Inc
Industrial Res Limited
Victoria Link Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College Medicine Yeshiva Univ, Albert Einstein College Medicine Inc, Callaghan Innovation Res Limited, Com Affiliation Inc, Industrial Res Limited, Victoria Link Ltd filed Critical Albert Einstein College Medicine Yeshiva Univ
Publication of BR0313664A publication Critical patent/BR0313664A/pt
Publication of BRPI0313664B1 publication Critical patent/BRPI0313664B1/pt
Publication of BRPI0313664B8 publication Critical patent/BRPI0313664B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Seal Device For Vehicle (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

compostos inibidores de nucleosídeo fosforilase e nucleosidases, suas composições e seus usos. a presente invenção se refere a compostos de formula geral (i) os quais são inibidores de nucleosídeo fosforilase de purina (pnp), fosforibosiltransferase de purina (pprt), fosforilase de 5'-metiltioadenosina (mtap), nucleosidade de 5'-metiltioadenosina (mtan) e/ou hidrolase de nucleosídeo (nh) . a invenção também se refere ao uso destes compostos no tratamento de doenças e infecções incluindo câncer, infecções bacterianas, infecções por protozoários e doença mediada da célula-t e composições farmacêuticas contendo estes compostos.
BRPI0313664A 2002-08-21 2003-08-21 compostos inibidores de nucleosídeo fosforilase e nucleosidases, suas composições e seus usos BRPI0313664B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ52091902 2002-08-21
NZ520919 2002-08-21
PCT/NZ2003/000186 WO2004018496A1 (en) 2002-08-21 2003-08-21 Inhibitors of nucleoside phosphorylases and nucleosidases

Publications (3)

Publication Number Publication Date
BR0313664A BR0313664A (pt) 2005-07-12
BRPI0313664B1 BRPI0313664B1 (pt) 2021-03-23
BRPI0313664B8 true BRPI0313664B8 (pt) 2021-05-25

Family

ID=31944950

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0313664A BRPI0313664B8 (pt) 2002-08-21 2003-08-21 compostos inibidores de nucleosídeo fosforilase e nucleosidases, suas composições e seus usos

Country Status (17)

Country Link
US (2) US7553839B2 (pt)
EP (1) EP1539783B1 (pt)
JP (1) JP4682314B2 (pt)
KR (1) KR101081226B1 (pt)
CN (1) CN100379750C (pt)
AT (1) ATE505474T1 (pt)
AU (1) AU2003258911B2 (pt)
BR (1) BRPI0313664B8 (pt)
CA (1) CA2496698C (pt)
CY (1) CY1111700T1 (pt)
DE (1) DE60336734D1 (pt)
DK (1) DK1539783T3 (pt)
ES (1) ES2363766T3 (pt)
PT (1) PT1539783E (pt)
RU (1) RU2330042C2 (pt)
SI (1) SI1539783T1 (pt)
WO (1) WO2004018496A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985848A (en) 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
SI1165564T1 (sl) * 1999-04-08 2009-08-31 Ind Res Ltd Postopek priprave inhibitorjev metabolizma nukleozidov
EP1539783B1 (en) 2002-08-21 2011-04-13 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside phosphorylases and nucleosidases
NZ523970A (en) * 2003-02-04 2005-02-25 Ind Res Ltd Process for preparing inhibitors of nucleoside phoshorylases and nucleosidases
RU2358975C2 (ru) * 2003-08-26 2009-06-20 Тейдзин Фарма Лимитед Пирролопиримидиноновые производные
US7557113B2 (en) 2003-08-26 2009-07-07 Teijin Pharma Limited Substituted pyrrolo[3,2-d]pyrimidine derivatives
NZ533360A (en) * 2004-06-04 2007-02-23 Ind Res Ltd Improved method for preparing 3-hydroxy-4-hydroxymethyl-pyrrolidine compounds
WO2006014913A2 (en) * 2004-07-27 2006-02-09 Biocryst Pharmaceuticals, Inc. Inhibitors of 5'-methylthioadenosine phosphorylase and 5'methylthioadenosine/s-adenosylhomocysteine nucleosidase
NZ540160A (en) * 2005-05-20 2008-03-28 Einstein Coll Med Inhibitors of nucleoside phosphorylases
US8541567B2 (en) * 2005-07-27 2013-09-24 Albert Einstein College Of Medicine Of Yeshiva University Transition state structure of 5′-methylthioadenosine/s-adenosylhomocysteine nucleosidases
NZ544187A (en) * 2005-12-15 2008-07-31 Ind Res Ltd Deazapurine analogs of 1'-aza-l-nucleosides
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
US8394950B2 (en) * 2006-02-22 2013-03-12 Industrial Research Limited Analogues of coformycin and their use for treating protozoan parasite infections
JP2009528996A (ja) * 2006-02-24 2009-08-13 インダストリアル リサーチ リミテッド ヌクレオシドホスホリラーゼ及びヌクレオシダーゼの阻害剤を用いて疾患を処置する方法
AU2006200809B2 (en) * 2006-02-24 2013-11-07 Albert Einstein College Of Medicine Of Yeshiva University Methods of treating cancer
JP2009527550A (ja) * 2006-02-24 2009-07-30 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ 癌を処置する方法
CN101094080B (zh) * 2006-06-22 2012-06-20 华为技术有限公司 一种即按即通系统中的计费方法
CA2662626C (en) * 2006-09-07 2016-07-26 Industrial Research Limited Acyclic amine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase
NZ575365A (en) 2006-09-07 2012-02-24 Ind Res Ltd Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases
WO2008079028A1 (en) * 2006-12-22 2008-07-03 Industrial Research Limited Azetidine analogues of nucleosidase and phosphorylase inhibitors
WO2009082247A1 (en) * 2007-12-21 2009-07-02 Industrial Research Limited Process for preparing immucillins having a methylene link
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
US20110190265A1 (en) * 2008-09-22 2011-08-04 Schramm Vern L Methods and compositions for treating bacterial infections by inhibiting quorum sensing
NZ595590A (en) * 2009-03-24 2013-11-29 Biocryst Pharm Inc Useful pharmaceutical salts of 7-[(3r,4r)-3-hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one
EP2454263B1 (en) * 2009-07-17 2018-06-13 Albert Einstein College of Medicine, Inc. 3-hydroxypyrrolidine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase
US9290501B2 (en) 2010-11-29 2016-03-22 Albert Einstein College Of Medicine, Inc. Methods, assays and compounds for treating bacterial infections by inhibiting methylthioinosine phosphorylase
WO2012122532A2 (en) * 2011-03-09 2012-09-13 Biocryst Pharmaceuticals, Inc. Compositions and methods for treatment of hyperuricemia
HRP20181667T1 (hr) 2011-07-22 2018-12-14 Glaxosmithkline Llc Pripravak
JP6063571B2 (ja) 2012-08-07 2017-01-18 アルバート アインシュタイン カレッジ オブ メディシン，インコーポレイティド ヘリコバクター・ピロリ感染の治療
EA026354B1 (ru) 2012-08-24 2017-03-31 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Пиразолопиримидиновые соединения
MX361933B (es) * 2012-11-12 2018-12-19 Victoria Link Ltd Sal y formas polimorficas de (3r,4s)-l-((4-amino-5h-pirrolo [3,2-d]pirimidin-7-il)metil)-4 (metiltiometil)pirodin-3-ol(mtdia).
EA028480B1 (ru) 2012-11-20 2017-11-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Новые соединения
AU2013348217B2 (en) 2012-11-20 2016-10-06 Glaxosmithkline Llc Novel compounds
BR112015011439A2 (pt) 2012-11-20 2017-07-11 Glaxosmithkline Llc composto, composição farmacêutica, composição de vacina, e, uso de um composto
US9452217B2 (en) 2013-06-22 2016-09-27 Nitor Therapeutics Methods for potentiating immune response for the treatment of infectious diseases and cancer
HK1232071A1 (zh) 2014-02-12 2018-01-05 Albert Einstein College Of Medicine, Inc. 使用mtan抑制剂治疗h.pylori感染
EP2913333A1 (en) * 2014-02-27 2015-09-02 Laboratoire Biodim 3H-thieno[3,4]pyrimidin-4-one and pyrrolopyrimidone as gram-positive antibacterial agents
CN108794628A (zh) * 2018-05-28 2018-11-13 广东工业大学 一种抗幽门螺杆菌的卵黄抗体制备方法及应用
GB202110403D0 (en) 2021-07-20 2021-09-01 Laevoroc Immunology Ulodesine Salt
GB202218782D0 (en) 2022-12-13 2023-01-25 Mehrling Thomas Purine nucleoside phosphorylase inhibitor for metabolic syndrome
CN116425751B (zh) * 2022-12-19 2024-01-23 艾立康药业股份有限公司 作为mat2a抑制剂的多环类化合物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2072123C (en) * 1989-10-31 2001-06-12 John A. Secrist, Iii Inhibitors of purine nucleoside phosphorylase
JPH07242668A (ja) * 1994-03-08 1995-09-19 Nippon Kayaku Co Ltd 新規なアゼチジン誘導体
FI971413L (fi) * 1994-10-05 1997-04-04 Chiroscience Ltd Puriini- ja guaniiniyhdisteet PNP:n estäjinä
KR100424934B1 (ko) * 1995-03-29 2004-07-27 다이호야쿠힌고교 가부시키가이샤 우라실유도체및이를함유하는항종양효과증강제및항종양제
AU1739097A (en) 1996-02-23 1997-09-10 Albert Einstein College Of Medicine Of Yeshiva University Enzyme detection/assay method and substrates
RU2183639C2 (ru) * 1996-10-16 2002-06-20 Ай-Си-Эн Фармасьютикалз, Инк. Пуриновые l-нуклеозиды, их аналоги и применение
US5985848A (en) 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
SI1165564T1 (sl) 1999-04-08 2009-08-31 Ind Res Ltd Postopek priprave inhibitorjev metabolizma nukleozidov
US6448799B1 (en) * 1999-09-30 2002-09-10 Hitachi Electronics Engineering Co., Ltd. Timing adjustment method and apparatus for semiconductor IC tester
JP4110347B2 (ja) * 1999-11-05 2008-07-02 大鵬薬品工業株式会社 抗ｈｉｖ剤
US7109331B2 (en) 2000-08-29 2006-09-19 Industrial Research Limited 5H-pyrrolo[3,2-d]pyrimidine nucleoside metabolism inhibitors
US6458799B1 (en) 2000-08-31 2002-10-01 Biocryst Pharmaceuticals, Inc. Deazaguanine analog, preparation thereof and use thereof
US7098334B2 (en) 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
EP1539783B1 (en) 2002-08-21 2011-04-13 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside phosphorylases and nucleosidases
NZ523970A (en) 2003-02-04 2005-02-25 Ind Res Ltd Process for preparing inhibitors of nucleoside phoshorylases and nucleosidases
NZ533360A (en) 2004-06-04 2007-02-23 Ind Res Ltd Improved method for preparing 3-hydroxy-4-hydroxymethyl-pyrrolidine compounds
WO2006014913A2 (en) 2004-07-27 2006-02-09 Biocryst Pharmaceuticals, Inc. Inhibitors of 5'-methylthioadenosine phosphorylase and 5'methylthioadenosine/s-adenosylhomocysteine nucleosidase
NZ540160A (en) 2005-05-20 2008-03-28 Einstein Coll Med Inhibitors of nucleoside phosphorylases
US8541567B2 (en) 2005-07-27 2013-09-24 Albert Einstein College Of Medicine Of Yeshiva University Transition state structure of 5′-methylthioadenosine/s-adenosylhomocysteine nucleosidases
NZ544187A (en) * 2005-12-15 2008-07-31 Ind Res Ltd Deazapurine analogs of 1'-aza-l-nucleosides
JP2009527550A (ja) * 2006-02-24 2009-07-30 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ 癌を処置する方法
JP2009528996A (ja) 2006-02-24 2009-08-13 インダストリアル リサーチ リミテッド ヌクレオシドホスホリラーゼ及びヌクレオシダーゼの阻害剤を用いて疾患を処置する方法
CA2662626C (en) * 2006-09-07 2016-07-26 Industrial Research Limited Acyclic amine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase
NZ575365A (en) 2006-09-07 2012-02-24 Ind Res Ltd Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases
EP2066671A1 (en) * 2006-09-26 2009-06-10 Albert Einstein College Of Medicine Of Yeshiva University Transition state structure of human 5'-methylthioadenosine phosphorylase
WO2008079028A1 (en) * 2006-12-22 2008-07-03 Industrial Research Limited Azetidine analogues of nucleosidase and phosphorylase inhibitors
WO2009082247A1 (en) 2007-12-21 2009-07-02 Industrial Research Limited Process for preparing immucillins having a methylene link
US20110190265A1 (en) 2008-09-22 2011-08-04 Schramm Vern L Methods and compositions for treating bacterial infections by inhibiting quorum sensing
EP2454263B1 (en) 2009-07-17 2018-06-13 Albert Einstein College of Medicine, Inc. 3-hydroxypyrrolidine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase

Also Published As

Publication number Publication date
JP4682314B2 (ja) 2011-05-11
CN100379750C (zh) 2008-04-09
US8173662B2 (en) 2012-05-08
WO2004018496A1 (en) 2004-03-04
JP2006501239A (ja) 2006-01-12
KR101081226B1 (ko) 2011-11-07
KR20050093756A (ko) 2005-09-23
EP1539783A4 (en) 2010-05-19
CN1692120A (zh) 2005-11-02
EP1539783A1 (en) 2005-06-15
CA2496698A1 (en) 2004-03-04
ATE505474T1 (de) 2011-04-15
RU2005107714A (ru) 2006-01-20
US20060160765A1 (en) 2006-07-20
EP1539783B1 (en) 2011-04-13
BR0313664A (pt) 2005-07-12
CA2496698C (en) 2012-01-24
BRPI0313664B1 (pt) 2021-03-23
PT1539783E (pt) 2011-06-01
DK1539783T3 (da) 2011-06-20
CY1111700T1 (el) 2015-10-07
HK1085219A1 (zh) 2006-08-18
AU2003258911A1 (en) 2004-03-11
US20090239885A1 (en) 2009-09-24
US7553839B2 (en) 2009-06-30
SI1539783T1 (sl) 2011-08-31
AU2003258911B2 (en) 2009-11-19
ES2363766T3 (es) 2011-08-16
RU2330042C2 (ru) 2008-07-27
DE60336734D1 (de) 2011-05-26

Similar Documents

Publication Publication Date Title
BRPI0313664B8 (pt) compostos inibidores de nucleosídeo fosforilase e nucleosidases, suas composições e seus usos
ATE552259T1 (de) Inhibitoren von nukleosidphosphorylasen und - nukleosidasen
EP2057165A4 (en) AZYCLIC AMININHIBITORS OF NUCLEOSIDE PHOSPHOLE LASES AND HYDROLASES
MEP36208A (en) Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
MEP13408A (en) Cdk inhibiting pyrimidines, production thereof and their use as medicaments
CY1106933T1 (el) Ενωσεις πυριμιδινης
NO20035524D0 (no) 4'-substituerte nukleosider
TR200102020T2 (tr) Raf kinaz inhibitörleri olarak w-karboksiaril sübstitüe edilmiş difenil üreler.
NO20053144L (no) Chk-, Pdk- og Akt-inhibitorpyrimidiner, deres fremstilling og anvendelse som famasoytiske midler.
CY1108146T1 (el) ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ β-ΑΜΙΝΟ-ΕΤΕΡΟΚΥΚΛΙΚΗΣ-ΔΙΠΕΠΤΙΔΥΛΙΚΗΣ ΠΕΠΤΙΔΑΣΗΣ ΓΙΑ ΤΗΝ ΑΓΩΓΗ Ή ΠΡΟΛΗΨΗ ΤΟΥ ΔΙΑΒΗΤΗ
CY1117217T1 (el) Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξοοξικης πιπεραζινης
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
BR9911612A (pt) Composições de pirrolo[2,3d]pirimidina e seus usos
BR0208154A (pt) Inibidores de fosfodiesterase 3',5'-mono-fosfato guanosina cìclica
JO2534B1 (en) Pyrimidines carrying alternatives of sulfoximine as CDK and / or VEGF inhibitors and their production and use as pharmaceutical agents
CY1106476T1 (el) Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες
MX2009005011A (es) Imidazopirazinas como inhibidores de proteina quinasa.
NO20035583D0 (no) Imidazo` 1,2-A pyridinderivater for profylakse og behandling av herpes virale infeksjoner
MY133995A (en) 6-phenylpyrrolopyrimidinedione derivatives
UA83041C2 (ru) Композиция, которая включает ингибитор pde4 и ингибитор pde5
WO2003106384A3 (en) Novel boronic chalcone derivatives and uses thereof
WO2006014913A3 (en) Inhibitors of 5'-methylthioadenosine phosphorylase and 5'methylthioadenosine/s-adenosylhomocysteine nucleosidase
DE60318694D1 (de) 4-(pyrrolopyrimidin-6-yl)benzolsulfonamidderivate
HRP20050184B1 (hr) Uporaba alkilfosfoholina u kombinaciji s protutumorskim lijekovima
PA8590801A1 (es) Derivados de nucleosido antivirales

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNI

Free format text: SEDE DO SEGUNDO TITULAR ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070123928/RJ DE 04/09/2007.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNI

B25A Requested transfer of rights approved

Owner name: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNI

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 11.2 NA RPI NO 2476 DE 19/06/2018 POR TER SIDO INDEVIDA.

B25A Requested transfer of rights approved

Owner name: VICTORIA LINK LIMITED (NZ) ; ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US)

Owner name: VICTORIA LINK LIMITED (NZ) ; ALBERT EINSTEIN COLLE

B25D Requested change of name of applicant approved

Owner name: VICTORIA LINK LIMITED (NZ) ; ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US)

Owner name: VICTORIA LINK LIMITED (NZ) ; ALBERT EINSTEIN COLLE

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/08/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF